Logo
x

Search

Subscribe Now

lib therapeutics

LIB Therapeutics Reports the US FDA’s BLA Acceptance for Lerodalcibep to Reduce LDL-Cholesterol in Cardiovascular Patients

LIB Therapeutics Reports the US FDA’s BLA Acceptance for Lerodalcibep to Reduce LDL-Cholesterol in Cardiovascular Patients

  • February 11, 2025
LIB Therapeutics Signs an Agreement with Hasten Biopharmaceutical to Develop and Commercialize Lerodalcibep in Greater China

LIB Therapeutics Signs an Agreement with Hasten Biopharmaceutical to Develop and Commercialize Lerodalcibep in Greater China

  • September 13, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.